Company Encyclopedia
View More
name
Immutep
IMMP.US
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525.
1.946 T
IMMP.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking126/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-36.88%E
    • Profit Margin-1218.02%E
    • Gross Margin-1117.55%E
  • Growth ScoreC
    • Revenue YoY28.52%A
    • Net Profit YoY-40.79%D
    • Total Assets YoY-23.82%E
    • Net Assets YoY-25.86%E
  • Cash ScoreB
    • Cash Flow Margin-8.21%D
    • OCF YoY28.52%A
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreA
    • Gearing Ratio8.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immutep Selects 30 mg Efti as Optimal Dose After Successful AIPAC-003 Trial Completion

    Immutep Ltd. announced successful completion of the AIPAC-003 Phase II trial, establishing 30 mg as the optimal dose for eftilagimod alfa in metastatic breast cancer treatment. The trial met FDA's Project Optimus requirements, showing strong response rates and immune activation. Results will be presented at the 2025 San Antonio Breast Cancer Symposium.

    Reuters·
    US
    IMMP
    +4.71%
    Reuters·
    US
    IMMP
    +4.71%

    High Growth Tech Stocks In Australia For November 2025

    The article discusses high-growth tech stocks in Australia for November 2025, highlighting companies like Immutep, PYC Therapeutics, and Xero. These companies are noted for their impressive revenue and earnings growth, despite broader economic challenges. Immutep is advancing in cancer immunotherapy, PYC Therapeutics is focusing on RNA therapeutics, and Xero is expanding its online business solutions. The article emphasizes the importance of strategic R&D investments and leadership enhancements in driving growth in the tech sector.

    Simplywall·
    US
    IMMP
    +4.71%
    Simplywall·
    US
    IMMP
    +4.71%

    Immutep Reports Positive Phase II Results for Eftilagimod Alfa in Soft Tissue Sarcoma

    Immutep Ltd. announced positive Phase II results for eftilagimod alfa (efti) in treating soft tissue sarcoma. The EFTISARC-NEO trial showed significant immune activation and a 51.5% rate of tumour hyalinization and fibrosis. The study also reported significant increases in immune biomarkers and cytokines. The project received the Golden Scalpel Award in Poland for its innovation in oncology research. Data were presented at the CTOS 2025 Annual Meeting.

    Reuters·
    US
    IMMP
    +4.71%
    Reuters·
    US
    IMMP
    +4.71%

    Immutep’s EFTISARC-NEO Trial Shows Promising Results in Soft Tissue Sarcoma

    Immutep Ltd (AU:IMM) announced promising results from its EFTISARC-NEO Phase II trial for soft tissue sarcoma, presented at the CTOS 2025 Annual Meeting. The trial showed significant tumor hyalinization/fibrosis with a combination of eftilagimod alfa, radiotherapy, and KEYTRUDA, indicating a strong immune response and potential for improved patient outcomes. The latest analyst rating for AU:IMM is a Hold with a price target of A$0.50. Immutep focuses on immunotherapy for cancer and autoimmune diseases, with a current market cap of A$375.3M.

    Tip Ranks·
    US
    IMMP
    +4.71%
    Tip Ranks·
    US
    IMMP
    +4.71%

    Immutep Advances Key Clinical Trials and Strengthens Financial Position

    Immutep Limited (IMMP) has reported significant advancements in its clinical trials and financial status in its Q1 FY26 activities report. The company is progressing with its TACTI-004 Phase III trial for eftilagimod alfa in non-small cell lung cancer, with over 100 sites open for enrollment. It also received positive FDA feedback for its head and neck cancer program and launched a new Phase II trial for breast cancer. Immutep holds A$109.85 million in cash, ensuring operations through 2026. Analyst ratings suggest a Hold with a $1.50 price target, while Spark rates it Neutral due to ongoing financial challenges.

    Tip Ranks·
    US
    IMMP
    +4.71%
    Tip Ranks·
    US
    IMMP
    +4.71%
    © 2025 Longbridge｜Disclaimer